

COMMERCIAL LEADERSHIP APPOINTMENTS

Highlights

- AROA has appointed Michael Lynskey as Chief Commercial Officer and Mike Falcon as General Manager – US Commercial.
- The appointments strengthen AROA's commercial leadership across the US and global advanced wound healing markets.
- The increased leadership capacity will support growth of the Myriad™ and Symphony™ portfolios, and broader adoption of AROA ECM™ technology.

Aroa Biosurgery Limited (ASX: ARX) ("AROA" or the "Company") announces the recent appointments of Michael Lynskey and Mike Falcon to its US-based commercial team.

AROA has been investing in expanding its commercial organisation to support its growth strategy and adoption of its AROA ECM™ technology. These appointments add seasoned leadership capability to support continued momentum across the Myriad product portfolio, and to capitalise on the recent market reset that has increased the opportunity for AROA's outpatient product, Symphony.

Michael Lynskey has been appointed as the Chief Commercial Officer and is a member of the Executive Leadership team. In this role, he will focus on leading AROA's global commercial growth strategy. He brings more than 20 years' experience driving global growth in advanced wound healing technology. He joins AROA from Smith+Nephew, where he has held multiple senior leadership roles globally throughout his 11-year tenure. Previously, Michael has held leadership roles at Stryker and Johnson & Johnson.

Mike Falcon has been appointed General Manager – US Commercial, strengthening AROA's leadership team as the Company continues to expand its presence and market share in the United States. In this position, he will lead AROA's U.S. commercial organisation. Prior to joining AROA, Mike held multiple commercial leadership roles during a 10-year tenure at LifeNet Health, where he gained extensive experience in advanced wound healing and biologics. He previously held leadership positions with Biomet and Johnson & Johnson.

AROA CEO, Brian Ward says: "Michael and Mike bring significant commercial and market development experience, and their appointments strengthen our ability to execute our growth strategy in the US and beyond."

<ENDS>

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

Contact

investor@aroa.com

About AROA™

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'.

We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix bioscaffold derived from ovine (sheep) forestomach.

Over 7 million AROA devices have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELABio, Inc.

Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com